IBDEI3AT ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,59,0)
 ;;=PROCEDURE CODES^3^12
 ;;^UTILITY(U,$J,358.4,60,0)
 ;;=FAMILY TRAINING-GROUP^2^12
 ;;^UTILITY(U,$J,358.4,61,0)
 ;;=RECREATION THERAPY DX^1^13
 ;;^UTILITY(U,$J,358.4,62,0)
 ;;=1-1 THERAPEUTIC PROCEDURES^1^14
 ;;^UTILITY(U,$J,358.4,63,0)
 ;;=EDUCATION/TRAINING^3^14
 ;;^UTILITY(U,$J,358.4,64,0)
 ;;=TEAM CONFERENCE^6^14
 ;;^UTILITY(U,$J,358.4,65,0)
 ;;=ASSESSMENT^2^14
 ;;^UTILITY(U,$J,358.4,66,0)
 ;;=FAMILY TRAINING^4^14
 ;;^UTILITY(U,$J,358.4,67,0)
 ;;=SPECIALTY PROCEDURES-INDIVIDUAL^5^14
 ;;^UTILITY(U,$J,358.4,68,0)
 ;;=RECREATION THERAPY DX^1^15
 ;;^UTILITY(U,$J,358.4,69,0)
 ;;=RESPIRATORY^10^16
 ;;^UTILITY(U,$J,358.4,70,0)
 ;;=SLEEP TESTING AND EVAL^11^16
 ;;^UTILITY(U,$J,358.4,71,0)
 ;;=PULMONARY FUNCTION TESTS^9^16
 ;;^UTILITY(U,$J,358.4,72,0)
 ;;=ABG/OX/TRANSCUTANEUOUS^1^16
 ;;^UTILITY(U,$J,358.4,73,0)
 ;;=HOME OXYGEN CLINIC^6^16
 ;;^UTILITY(U,$J,358.4,74,0)
 ;;=CPAP^2^16
 ;;^UTILITY(U,$J,358.4,75,0)
 ;;=EDUCATION/TRAINING^3^16
 ;;^UTILITY(U,$J,358.4,76,0)
 ;;=PROLONGED CLINICAL STAFF SERVICES^8^16
 ;;^UTILITY(U,$J,358.4,77,0)
 ;;=HOME SLEEP STUDIES^7^16
 ;;^UTILITY(U,$J,358.4,78,0)
 ;;=TELEHEALTH PATIENT SITE^12^16
 ;;^UTILITY(U,$J,358.4,79,0)
 ;;=NEW PATIENT^2^17
 ;;^UTILITY(U,$J,358.4,80,0)
 ;;=ESTABLISHED PATIENT^1^17
 ;;^UTILITY(U,$J,358.4,81,0)
 ;;=CONSULTATIONS^3^17
 ;;^UTILITY(U,$J,358.4,82,0)
 ;;=PULMONARY DIAGNOSES^2^18
 ;;^UTILITY(U,$J,358.4,83,0)
 ;;=SLEEP DX PRELIMINARY^3^18
 ;;^UTILITY(U,$J,358.4,84,0)
 ;;=SLEEP DX CONFIRMED^4^18
 ;;^UTILITY(U,$J,358.4,85,0)
 ;;=OTHER SLEEP RELATED DX^6^18
 ;;^UTILITY(U,$J,358.4,86,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^5^18
 ;;^UTILITY(U,$J,358.4,87,0)
 ;;=OBESITY & BMI DX^1^18
 ;;^UTILITY(U,$J,358.4,88,0)
 ;;=SPECIAL SERVICES^6^19
 ;;^UTILITY(U,$J,358.4,89,0)
 ;;=TREATMENT^7^19
 ;;^UTILITY(U,$J,358.4,90,0)
 ;;=MISCELLANEOUS^4^19
 ;;^UTILITY(U,$J,358.4,91,0)
 ;;=IMMUNIZATIONS^3^19
 ;;^UTILITY(U,$J,358.4,92,0)
 ;;=CHEMO ADMINISTRATION^1^19
 ;;^UTILITY(U,$J,358.4,93,0)
 ;;=CHEMO DRUGS^2^19
 ;;^UTILITY(U,$J,358.4,94,0)
 ;;=OTHER DRUGS^5^19
 ;;^UTILITY(U,$J,358.4,95,0)
 ;;=NEW PATIENT^2^20
 ;;^UTILITY(U,$J,358.4,96,0)
 ;;=ESTABLISHED PATIENT^1^20
 ;;^UTILITY(U,$J,358.4,97,0)
 ;;=CONSULTATIONS^3^20
 ;;^UTILITY(U,$J,358.4,98,0)
 ;;=POST OP^4^20
 ;;^UTILITY(U,$J,358.4,99,0)
 ;;=ANEMIA^2^21
 ;;^UTILITY(U,$J,358.4,100,0)
 ;;=BREAST & GYN NEOPLASMS^2^21
 ;;^UTILITY(U,$J,358.4,101,0)
 ;;=COAGULATION DISORDERS^3^21
 ;;^UTILITY(U,$J,358.4,102,0)
 ;;=COUNSELING & SCREENING^4^21
 ;;^UTILITY(U,$J,358.4,103,0)
 ;;=GENITOURINARY NEOPLASMS^5^21
 ;;^UTILITY(U,$J,358.4,104,0)
 ;;=GI CANCER^6^21
 ;;^UTILITY(U,$J,358.4,105,0)
 ;;=HEAD/NECK/LUNG CANCER^7^21
 ;;^UTILITY(U,$J,358.4,106,0)
 ;;=HEMOGLOBINOPATHIES^9^21
 ;;^UTILITY(U,$J,358.4,107,0)
 ;;=LYMPHOID NEOPLASMS^10^21
 ;;^UTILITY(U,$J,358.4,108,0)
 ;;=METASTATIC SITES^11^21
 ;;^UTILITY(U,$J,358.4,109,0)
 ;;=MISC. NEOPLASMS^12^21
 ;;^UTILITY(U,$J,358.4,110,0)
 ;;=MYELOID NEOPLASMS/DISORDERS^13^21
 ;;^UTILITY(U,$J,358.4,111,0)
 ;;=PERSONAL HX OF CANCER^15^21
 ;;^UTILITY(U,$J,358.4,112,0)
 ;;=OTHER^14^21
 ;;^UTILITY(U,$J,358.4,113,0)
 ;;=HEMATOLOGICAL^8^21
 ;;^UTILITY(U,$J,358.4,114,0)
 ;;=SYMPTOMS^17^21
 ;;^UTILITY(U,$J,358.4,115,0)
 ;;=TREATMENT^18^21
 ;;^UTILITY(U,$J,358.4,116,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^16^21
 ;;^UTILITY(U,$J,358.4,117,0)
 ;;=ABNORMAL LAB TEST RESULTS^1^21
 ;;^UTILITY(U,$J,358.4,118,0)
 ;;=SPECIAL SERVICES^10^22
